February 2015- Volume 11, Issue 2

February 2015

In this Issue

Discovery

Enzyme provides an inroad

Enzyme provides an inroad

Scientists at Scripps discover enzyme for treating brain inflammation in patients with PHARC, Parkinson’s, Alzheimer’s, ALS and MS

Mersana and Takeda expand ADC partnership

Mersana and Takeda expand ADC partnership

Aim is to create novel Fleximer antibody-drug conjugate candidates to include additional oncology-relevant targets

Exploring Ebola efforts

Exploring Ebola efforts

Kymab to lead a consortium to pursue antibodies against Ebola virus

Diagnostics

First to assess BRCA status

First to assess BRCA status

Myriad receives FDA approval on companion diagnostic for Lynparza in ovarian cancer

Two deals; one goal

Two deals; one goal

Amarantus expands its reach with acquisition deal and license agreement

Revolution in immuno-oncology

Revolution in immuno-oncology

Intratumoral cancer immunotherapy enhances local delivery and uptake of DNA-based immune-targeting agents

Massing diagnostic efforts in Massachusetts

Massing diagnostic efforts in Massachusetts

Diagnostics For All issues challenge grant for multi-institution Ebola partnership

Research & Development

Sequencing for success

Sequencing for success

Roche acquires Bina Technologies, enters genomic informatics market

Adding to the mix

Adding to the mix

Rockland ventures into aptamer market with SBIR funding

Living Lab expands

Living Lab expands

FEI and OHSU install complete correlative microscopy workflow in newly built collaborative science facility

Immune checkpoint strides

Immune checkpoint strides

Research indicates cancer immunotherapies have potential for a long-lasting response to treatment

Roche teams with Foundation Medicine

Roche teams with Foundation Medicine

Molecular information collaboration leverages companies’ strengths to advance progress of personalized treatments for oncology

Business & Government Policy

$25-million launch for Vtesse

$25-million launch for Vtesse

Company to work with NIH on drugs for Niemann-Pick disease and other life-threatening rare diseases

Converging on growth

Converging on growth

Biogen Idec expands pain portfolio with Covergence expertise, Phase 2 drug candidate

For your approval

For your approval

A collection of recent regulatory approvals and actions globally

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Shire to snap up NPS Pharma for $5.2B

Shire to snap up NPS Pharma for $5.2B

Acquisition is a further step by Shire toward building itself into a leading biotech

Clinical Trials

Taking aim at AT

Taking aim at AT

Alnylam reports encouraging Phase 1 results for hemophilia RNAi therapeutic

A new class of opioid therapeutic

A new class of opioid therapeutic

Cara Therapeutics reports positive top-line data from Phase 1b trial of IV CR845 in dialysis patients with uremic pruritus

Studies in motion

Studies in motion

Auspex scores in three clinical trials involving SD-809

Arresting cardiac risks

Arresting cardiac risks

FDA gives go-ahead for earlier cardiac safety testing

Real talk on RASAL2

Real talk on RASAL2

GIS study finds RASAL2 to be upregulated in triple-negative or estrogen receptor-negative breast cancer tumors

Preclinical

Repurposed duo vs. Alzheimer’s

Repurposed duo vs. Alzheimer’s

Pharnext’s pleotherapy shows synergistic effects in PXT-864 for Alzheimer’s disease

Attacking an early MS sign

Attacking an early MS sign

Collaboration keeps first-in-class neuroprotective agent in acute optic neuritis on track for early clinical trials

Rebranding and reaching out

Rebranding and reaching out

Expansion, conference are milestones for Crown Bioscience

Pharma strikes sweet deal with Hershey company

Pharma strikes sweet deal with Hershey company

Cipher pays $500K for assets of Melanovus; expands dermatology pipeline

Commentary

The tyranny of averages

The tyranny of averages

There are plenty of numbers in the life-sciences, pharma and the like, but we need to look for more meaning and context for them

A grad student Q&A with Peter T. Kissinger

A grad student Q&A with Peter T. Kissinger

What 'Dear Abby' did for relationship advice and other wisdom about life, DDNews columnist Peter T. Kissinger seeks to do with a Q&A-style piece aimed at answering some of the (presumably) pressing concerns of grad students and postdocs

Special Reports

Signs of intelligent biomarkers

Signs of intelligent biomarkers

Lots of genomics data, but how much knowledge?

Feature

Pittcon 2015 provides breadth and depth

Pittcon 2015 provides breadth and depth

Pittcon maintains its reach into pharma, biotech and life sciences while adding a new focus on a younger demographic

Q&A

Q&A: Opioid addiction and the quest for a solution

Q&A: Opioid addiction and the quest for a solution

DDNews talks with Dr. Mark A. Sirgo, of BioDelivery Sciences Inc. about how his company and its collaborator Endo Pharmaceuticals are working together to help resolve the problem of addiction to narcotic painkillers

Editor's Focus

Entering the 21st century…precisely?

Entering the 21st century…precisely?

Congress and President Obama are both talking big talk about stepping into the 21st century boldly in terms of healthcare, but what are they really telling us and what will they actually do?
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 17 • Issue 1 • January 2021

December 2020/January 2021

December 2020/January 2021 issue